

- **Vulcan Accelerator**
- **Introductory Presentation**
- Last Updated: August 13 2020



Contents

Background

FHIR Accelerator

Organizational Structure

Use Case Development

Vulcan Status

- **Thank you for your interest in joining Vulcan!**
- **This document provides an overview of the history and goals of Vulcan.**

• Vulcan HL7 FHIR grew out of the increasingly digital healthcare environment

- The growing digitalization in healthcare brings along modernized electronic health record standards such as HL7 FHIR.
- Maturity in this space varies across the markets; however, the transition to a more digital environment is happening.
- Several Accelerators exist already to spur development of digital solutions for healthcare:
 - *Project Argonaut* (providers to providers)
 - *Project DaVinci* (providers to payers)


Experts Blazing the Path Forward for Research

The September 2019 HL7 FHIR® Conference in Atlanta included a half-day forum drawing participation across government, academia and industry.



The goal of the forum was to help the research community align toward leveraging HL7 FHIR® for more effective acquisition, exchange and use of data for clinical research.

- **Vulcan HL7 FHIR: Who Are We?**
- Members of the Clinical and Translational Clinical Research Communities



• Convening Members of Vulcan



Amy Cramer
Steering Committee
Co-Chair



Anita Walden
Operations Committee
NCATS-CTSA Site



Boris Brodsky
Operations Committee
BR&R



Chris Chute
Steering Committee
NCATS-CTSA Site



Christi Denney
Operations Committee
TransCelerate



Chuck Jaffe
Steering Committee
HL7



Clem McDonald
Steering Committee
NLM



Davera Gabriel
Operations Committee
NCATS-CTSA Site



Debi Willis
Steering Committee
HL7 Patient Advocate



Ed Hammond
Steering Committee
NCATS-CTSA Site



Jesper Kjaer
Operations Committee
Danish Medicines Agency



Jose Galvez
Steering Committee
FDA



Hugh Glover
Operations Committee
HL7 BR&R



Karen Van Hentenryck
Steering Committee
HL7



Ken Gersing
Steering Committee
NCATS



Linda King
Steering Committee
SCDM



Mary Ann Slack
Steering Committee
FDA



Meredith Zozus
Steering Committee
NCATS-CTSA Site



Mika Ogasawara
Operations Committee
TransCelerate



Mike Buckley
Operations Committee
SCDM



Rakesh Maniar
Operations Committee
TransCelerate



Rob Goodwin
Steering Committee
Co-Chair, TransCelerate



Teresa Zayas Caban
Steering Committee
NLM



Viet Nguyen
Steering Committee
FHIR SME



Wayne Kubick
Operations Committee
HL7



• The Goals of Vulcan



- 1 • Bridge Existing Gaps: Work to close gap between clinical care and clinical research to improve patient lives, decrease costs and improve efficiency
- 2 • Strategically Connect Industry Collaborations: Coordinate strategy between stakeholders and leverage existing work within HL7 and other groups including FDA, Danish Medical Agency, NCATS, NLM, SCDM, TransCelerate, and global research sites
- 3 • Maximize Collective Resources: Leverage shared community and resources to be able to communicate the return on investment and return on value that a unified network could realize to various parties, and provide comprehensive recommendations to global regulators
- 4 • Deliver Integrated Tools and Solutions: Develop necessary FHIR Research Resources to maturity. Vulcan will handle identified and prioritized use cases for secondary use of EHR data that meet interested parties needs and goals

• What is an HL7 Accelerator?

- HL7 Accelerator Program


- HL7 created the FHIR Accelerator Program to motivate and support market collaborations seeking to accelerate the availability of FHIR to tackle important interoperability needs.
- FHIR (Fast Healthcare Interoperability Resources) is an HL7 standard that enables secure exchange of healthcare information.
- Industry adoption of FHIR is advancing rapidly as witnessed not only by availability of FHIR in EHRs, but also in smart phone and platform company solutions.

About



- The Vulcan accelerator is focused on data mapping and standards for particular use cases that connect healthcare with clinical and translational research.
- It is a collaborative membership-based project group with defined membership operated under HL7.
- It is modeled after success of other accelerators (DaVinci, Argonaut, etc.), but it is also groundbreaking in many respects.
- Key organizations initiating this accelerator include FDA, NCATS, NLM, SCDM, TransCelerate, and academic research sites.

• Vulcan Organizational Structure



Advisory Council
Thought leaders nominated by the Steering Committee who serves as a voice for their area of expertise and/or the health sector they represent and not their own organization.

Steering Committee

Set strategic direction; prioritize activities and approve use cases projects, make financial decisions. Founding members represented.

Operations Committee


Develop and recommend use case proposals, oversee operation and delivery of use case projects. All members represented.

Project Teams

Formed to carry out use case projects. All members have the opportunity to participate in the project teams they chose.

Vulcan Use Case Assessment Prioritization

- The Operations Committee will identify and develop potential use cases, scoring them on several measures. The Steering Committee will identify prioritization to drive project initiation. The initial assessment resulted in many potential use cases with three primary areas identified.



• Vulcan Status

